文献速递淋巴瘤造血干细胞移植与细胞治疗

第三代抗CD19 CAR-T细胞治疗复发/难治性慢性淋巴细胞白血病:一项1/2期研究

Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
PubMed 文献 · Leukemia · 2024-08-27

该研究为研究者发起的1/2期试验,评估第三代抗CD19 CAR-T(HD-CAR-1)在复发/难治性CLL及B细胞淋巴瘤中的递增剂量。9例重度经治CLL患者接受1×10^6至200×10^6 CART/m^2治疗,未观察到神经毒性,1例3级细胞因子释放综合征;第90天6例(67%)达CR,其中5例(83%)MRD不可测;中位随访27个月,2年PFS和OS分别为30%和69%。

要点

  • 9例重度经治r/r CLL患者接受HD-CAR-1,剂量范围1×10^6至200×10^6 CART/m^2。
  • 未观察到神经毒性,1例发生3级细胞因子释放综合征。
  • 第90天6例(67%)达CR,其中5例(83%)MRD不可测;中位随访27个月,2年PFS 30%、OS 69%。

核心结论

  • HD-CAR-1在r/r CLL中显示出令人鼓舞的疗效和极低的治疗相关毒性,为r/r CLL患者提供新的治疗选择。

研究设计与样本

  • 研究者发起的1/2期试验,评估第三代抗CD19 CAR-T(HD-CAR-1)在r/r CLL和B细胞淋巴瘤患者中的递增剂量。
  • CLL入组标准为二线治疗失败,包括至少一种通路抑制剂和/或异基因造血干细胞移植。
  • 9例重度经治患者接受HD-CAR-1,剂量水平为1×10^6至200×10^6 CART/m^2。
  • 所有患者的HD-CAR-1均在本院(in-house)成功制备。
  • 试验注册号:NCT03676504。

主要发现

  • 未观察到神经毒性,观察到1例3级细胞因子释放综合征。
  • 第90天,6例患者(67%)达到CR,其中5例(83%)MRD不可测。
  • 中位随访27个月,2年PFS为30%,2年OS为69%。
  • 缓解者的HD-CAR-1产品中CD4+ T细胞显著多于非缓解者。
  • 非缓解者中观察到高表达CD39和/或CD197的效应记忆样CD8+ T细胞强烈富集。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Third-generation chimeric antigen receptor T cells (CARTs) for relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) may improve efficacy compared to second-generation CARTs due to their enhanced CAR design. We performed the first phase 1/2 investigator-initiated trial evaluating escalating doses of third-generation CARTs (HD-CAR-1) targeting CD19 in patients with r/r CLL and B-cell lymphoma. CLL eligibility criteria were failure to two therapy lines including at least one pathway inhibitor and/or allogeneic hematopoietic cell transplantation. Nine heavily pretreated patients received HD-CAR-1 at dose levels ranging from 1 × 106 to 200 × 106 CART/m2. In-house HD-CAR-1 manufacturing was successful for all patients. While neurotoxicity was absent, one case of grade 3 cytokine release syndrome was observed. By day 90, six patients (67%) attained a CR, five of these (83%) with undetectable MRD. With a median follow-up of 27 months, 2-year PFS and OS were 30% and 69%, respectively. HD-CAR-1 products of responders contained significantly more CD4 + T cells compared to non-responders. In non-responders, a strong enrichment of effector memory-like CD8 + T cells with high expression of CD39 and/or CD197 was observed. HD-CAR-1 demonstrated encouraging efficacy and exceptionally low treatment-specific toxicity, presenting new treatment options for patients with r/r CLL. Trial registration: #NCT03676504.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Derigs P, Schubert ML, Dreger P, et al. Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study. Leukemia. 2024. PMID: 39192036. doi:10.1038/s41375-024-02392-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。